Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MM
MCID: MYL069
MIFTS: 85

Myeloma, Multiple (MM)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myeloma, Multiple

About this section

MalaCards integrated aliases for Myeloma, Multiple:

Name: Myeloma, Multiple 56 37 39
Multiple Myeloma 56 12 74 52 25 58 73 36 29 13 6 42 43 15 17 71 32
Plasma Cell Myeloma 12 52 58 54
Medullary Plasmacytoma 25 58 71
Plasma Cell Dyscrasia 52 25 71
Kahler Disease 52 25 58
Myelomatosis 52 25 58
Multiple Myeloma, Resistance to 56 6
Primary Systemic Amyloidosis 58 71
Primary Amyloidosis 58 71
Multiple Myeloma, Susceptibility to 56
Immunoglobulin Deposition Disease 71
Systemic Al Amyloidosis 58
Light-Chain Amyloidosis 58
Kahler-Bozzolo Disease 25
Plasma Cell Neoplasm 71
Plasma Cell Myelomas 25
Amyloidosis Primary 54
Myeloma - Multiple 52
Kahler's Disease 25
Al Amyloidosis 58
Mm 73

Characteristics:

Orphanet epidemiological data:

58
primary systemic amyloidosis
Inheritance: Not applicable;
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation


HPO:

31
myeloma, multiple:
Inheritance autosomal recessive inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Neuronal diseases Nephrological diseases Bone diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare systemic and rhumatological diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9538
OMIM 56 254500
KEGG 36 H00010
ICD9CM 34 203.0
MeSH 43 D009101
NCIt 49 C3242
SNOMED-CT 67 109989006 55921005
ICD10 32 C90.0
MESH via Orphanet 44 C531616 D009101
ICD10 via Orphanet 33 C90.0 E85.0 E85.1 more
UMLS via Orphanet 72 C0026764 C0268381
UMLS 71 C0026764 C0268381 C0281479 more
Sources

Summaries for Myeloma, Multiple

About this section
Genetics Home Reference : 25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting. Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumors within the bone, causing bone pain and an increased risk of fractures. If the tumors interfere with nerves near the bones, numbness or weakness in the arms or legs can occur. Affected individuals may also experience a loss of bone tissue, particularly in the skull, spine, ribs, and pelvis. The deterioration of bone can result in an excess of calcium in the blood (hypercalcemia), which can lead to nausea and loss of appetite, excessive thirst, fatigue, muscle weakness, and confusion. The abnormal plasma cells in multiple myeloma produce proteins that impair the development of normal blood cells. As a result, affected individuals may have a reduced number of red blood cells (anemia), which can cause fatigue, weakness, and unusually pale skin (pallor); a low number of white blood cells (leukopenia), which can result in a weakened immune system and frequent infections such as pneumonia; and a reduced number of platelets (thrombocytopenia), which can lead to abnormal bleeding and bruising. Kidney problems can also occur in this disorder, caused by hypercalcemia or by toxic proteins produced by the abnormal plasma cells. People with multiple myeloma typically develop the disorder around age 65. Over time, affected individuals can develop life-threatening complications, but the rate at which this happens varies widely. Some affected individuals are diagnosed incidentally when tests are done for other purposes and do not experience symptoms for years.

MalaCards based summary : Myeloma, Multiple, also known as multiple myeloma, is related to hyperplastic polyposis syndrome and leukemia, chronic lymphocytic. An important gene associated with Myeloma, Multiple is LIG4 (DNA Ligase 4), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Developmental Biology. The drugs Apixaban and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are osteopenia and pathologic fracture

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

NIH Rare Diseases : 52 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia , which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race , radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (MGUS ). Treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy , corticosteroid medications, targeted therapy , stem cell transplant , biological therapy , radiation therapy , surgery and/or watchful waiting .

OMIM : 56 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500)

MedlinePlus : 42 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include Bone pain, often in the back or ribs Fractures (broken bones) Weakness or fatigue Weight loss Frequent infections and fevers Feeling very thirsty Frequent urination Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

KEGG : 36 Multiple myeloma is a disorder in which malignant plasma cells accumulate, generally derived from one clone in the bone marrow. Intricate interactions occur between the bone-marrow microenvironment and the myeloma cells, frequently causing bone destruction, which in turn stimulates tumor growth. Often it is preceded by a premalignant tumor called monoclonal gammopathy of undetermined significance (MGUS). Multiple oncogenic events have been identified that have contributed to the pathogenesis of myeloma. Among the earliest genetic events are translocations of the immunoglobulin heavy-chain gene locus, which leads to dysregulation of oncogenes at translocation partner regions (cyclin D1 at 11q13, FGFR3/MMSET at 4p16.3, c-MAF at 16q23, and cyclin D3 at 6p21), and deletions of 13q14, the site of a putative tumor suppressor gene. Additional molecular events include epigenetic changes and activation of oncogenes (mutations of N-RAS and K-RAS, and changes in c-MYC), which are usually associated with disease progression.

UniProtKB/Swiss-Prot : 73 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Wikipedia : 74 Multiple myeloma (MM), also known as plasma cell myeloma and simple myeloma, is a cancer of plasma... more...

Sources

Related Diseases for Myeloma, Multiple

About this section

Diseases related to Myeloma, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1856)
# Related Disease Score Top Affiliating Genes
1 hyperplastic polyposis syndrome 33.9 TP53 KRAS BRAF
2 leukemia, chronic lymphocytic 33.7 TP53 PTPN11 NRAS MIR19A MIR181A2 MIR15A
3 leukemia, acute myeloid 33.6 TP53 PTPN11 NRAS MIR181A2 MIR15A MIR106B
4 hepatocellular carcinoma 33.2 TP53 PTPN11 NRAS MIR93 MIR25 MIR19A
5 colorectal cancer 33.1 TP53 NRAS MIR93 MIR32 MIR25 MIR19A
6 lung cancer 33.1 TP53 NRAS MIR93 MIR32 MIR25 MIR19A
7 hematologic cancer 32.9 TP53 PTPN11 MIR93 MIR25 MIR19A MIR15A
8 lung cancer susceptibility 3 32.8 TP53 NRAS MIR32 MIR15A MIR106B KRAS
9 bladder cancer 32.7 TP53 NRAS MIR93 MIR106B KRAS HRAS
10 leukemia, chronic myeloid 32.7 TP53 PTPN11 NRAS MIR19A KRAS HRAS
11 melanoma 32.6 TP53 NRAS MIR19A MIR181A2 MIR15A KRAS
12 lymphoma, non-hodgkin, familial 32.6 TP53 NRAS MIR15A CCND1 BRAF
13 renal cell carcinoma, nonpapillary 32.5 TP53 NRAS MIR93 MIR15A MIR106B HRAS
14 acute promyelocytic leukemia 32.4 TP53 NRAS MIR15A KRAS HRAS CDK4
15 gastric cancer 32.4 TP53 PTPN11 NRAS MIR93 MIR25 MIR106B
16 glioblastoma multiforme 32.4 TP53 NRAS KRAS IDH2 IDH1 HRAS
17 pancreatic cancer 32.4 TP53 MIR32 MIR25 MIR181A2 MIR15A KRAS
18 essential thrombocythemia 32.3 TP53 PTPN11 KRAS IDH2 IDH1 CCND1
19 skin melanoma 32.3 TP53 NRAS HRAS BRAF
20 leukemia 32.3 TP53 PTPN11 NRAS KRAS HRAS CCND1
21 neuroblastoma 32.2 TP53 PTPN11 NRAS MIR93 HRAS FGFR3
22 monoclonal gammopathy of uncertain significance 32.2 MIR19A HRAS FGFR3 CCND1
23 suppression of tumorigenicity 12 32.2 TP53 KRAS IDH1 HRAS CDK4 CCND1
24 endometrial cancer 32.1 TP53 PTPN11 NRAS KRAS HRAS CDK4
25 myelodysplastic syndrome 32.1 TP53 PTPN11 NRAS LIG4 KRAS IDH2
26 glioma 32.1 TP53 MIR25 MIR19A MIR181A2 MIR15A IDH2
27 myelofibrosis 32.1 TP53 IDH2 IDH1 HRAS
28 leukemia, acute lymphoblastic 32.1 TP53 PTPN11 KRAS HRAS CDK4
29 lymphoma 32.0 TP53 PTPN11 NRAS KMT2D CDK4 CCND1
30 gastric adenocarcinoma 32.0 TP53 NRAS MIR25 KRAS IDH1 HRAS
31 nodular malignant melanoma 31.9 TP53 NRAS HRAS CDK4 CCND1 BRAF
32 plasma cell leukemia 31.9 NRAS MIR19A KRAS FGFR3 CCND1
33 medulloblastoma 31.9 TP53 PTPN11 NRAS MIR19A LIG4 KMT2D
34 brain cancer 31.9 TP53 PTPN11 NRAS MIR25 MIR19A IDH2
35 squamous cell carcinoma, head and neck 31.8 TP53 MIR19A MIR15A KRAS IDH2 HRAS
36 squamous cell carcinoma 31.8 TP53 HRAS FGFR3 CCND1 BRAF
37 cholangiocarcinoma 31.8 TP53 KRAS IDH2 IDH1 CCND1 BRAF
38 eye disease 31.8 TP53 MIR93 MIR15A HRAS CDK4 CCND1
39 in situ carcinoma 31.8 TP53 HRAS CCND1
40 bladder urothelial carcinoma 31.8 TP53 NRAS KRAS KMT2D IDH1 HRAS
41 adenoma 31.8 TP53 KRAS CCND1 BRAF
42 nasopharyngeal carcinoma 31.8 TP53 NRAS MIR93 MIR15A HRAS CDK4
43 colorectal adenoma 31.8 TP53 MIR15A KRAS HRAS CCND1
44 skin carcinoma 31.8 TP53 NRAS HRAS CDK4 CCND1
45 cervical cancer 31.8 TP53 MIR93 MIR19A MIR15A MIR106B HRAS
46 nervous system disease 31.7 MIR93 MIR25 MIR19A MIR15A MIR106B
47 chromosome 13q14 deletion syndrome 31.7 TP53 MIR15A HRAS
48 intrahepatic cholangiocarcinoma 31.7 TP53 KRAS IDH2 IDH1 CCND1
49 systemic mastocytosis 31.7 PTPN11 NRAS IDH2 IDH1
50 sarcoma 31.7 TP53 NRAS KRAS HRAS FGFR3 CDK4

Graphical network of the top 20 diseases related to Myeloma, Multiple:



Diseases related to Myeloma, Multiple
Sources

Symptoms & Phenotypes for Myeloma, Multiple

About this section

Human phenotypes related to Myeloma, Multiple:

58 31 (show top 50) (show all 83)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000938
2 pathologic fracture 58 31 hallmark (90%) Very frequent (99-80%) HP:0002756
3 nephropathy 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000112
4 fatigue 58 31 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0012378
5 generalized muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0003324
6 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
7 nephrotic syndrome 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000100
8 bone pain 58 31 frequent (33%) Frequent (79-30%) HP:0002653
9 acute kidney injury 58 31 frequent (33%) Frequent (79-30%) HP:0001919
10 elevated serum creatinine 58 31 frequent (33%) Frequent (79-30%) HP:0003259
11 hyperproteinemia 58 31 frequent (33%) Frequent (79-30%) HP:0002152
12 increased circulating igg level 58 31 frequent (33%) Frequent (79-30%) HP:0003237
13 decreased circulating antibody level 31 frequent (33%) HP:0004313
14 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
15 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
16 abnormality of the bladder 58 31 occasional (7.5%) Occasional (29-5%) HP:0000014
17 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
18 tall stature 58 31 occasional (7.5%) Occasional (29-5%) HP:0000098
19 vertebral compression fractures 58 31 occasional (7.5%) Occasional (29-5%) HP:0002953
20 functional abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0012719
21 spinal cord compression 58 31 occasional (7.5%) Occasional (29-5%) HP:0002176
22 increased circulating iga level 58 31 occasional (7.5%) Occasional (29-5%) HP:0003261
23 abnormality of vitamin b12 metabolism 58 31 occasional (7.5%) Occasional (29-5%) HP:0004341
24 splenomegaly 58 31 very rare (1%) Very rare (<4-1%) HP:0001744
25 lymphadenopathy 58 31 very rare (1%) Very rare (<4-1%),Frequent (79-30%) HP:0002716
26 pleural effusion 58 31 very rare (1%) Very rare (<4-1%),Occasional (29-5%) HP:0002202
27 multiple myeloma 58 31 Frequent (79-30%) HP:0006775
28 macroglossia 58 Occasional (29-5%)
29 hepatomegaly 58 Frequent (79-30%)
30 malabsorption 58 Occasional (29-5%)
31 proteinuria 58 Frequent (79-30%)
32 renal insufficiency 58 Frequent (79-30%)
33 hypertrophic cardiomyopathy 58 Very frequent (99-80%)
34 dyspnea 58 Frequent (79-30%)
35 arrhythmia 58 Frequent (79-30%)
36 arthralgia 58 Frequent (79-30%)
37 abnormal blistering of the skin 58 Occasional (29-5%)
38 papule 58 Occasional (29-5%)
39 congestive heart failure 58 Frequent (79-30%)
40 hepatitis 58 Occasional (29-5%)
41 xerostomia 58 Occasional (29-5%)
42 hematuria 58 Occasional (29-5%)
43 gastrointestinal hemorrhage 58 Occasional (29-5%)
44 hypertension 58 Occasional (29-5%)
45 decreased antibody level in blood 58 Frequent (79-30%),Occasional (29-5%)
46 constipation 58 Frequent (79-30%)
47 purpura 58 Occasional (29-5%)
48 osteoarthritis 58 Occasional (29-5%)
49 skeletal muscle hypertrophy 58 Occasional (29-5%)
50 goiter 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
multiple myeloma

Laboratory Abnormalities:
paraproteinemia
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)

Clinical features from OMIM:

254500

GenomeRNAi Phenotypes related to Myeloma, Multiple according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 CDK4 FGFR3
2 Decreased cell migration GR00055-A-3 9.26 BRAF HRAS
3 Reduced mammosphere formation GR00396-S 9.23 BRAF CCND1 CDK4 HRAS IDH2 KRAS

MGI Mouse Phenotypes related to Myeloma, Multiple:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 BRAF CCND1 CDK4 FGFR3 HRAS IDH1
2 cardiovascular system MP:0005385 10.25 BRAF CCND1 CDK4 HRAS IDH2 KMT2D
3 craniofacial MP:0005382 10.24 BRAF CCND1 CDK4 FGFR3 HRAS KMT2D
4 digestive/alimentary MP:0005381 10.22 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
5 hematopoietic system MP:0005397 10.2 BRAF CCND1 CDK4 FGFR3 IDH1 KMT2D
6 immune system MP:0005387 10.17 BRAF CCND1 CDK4 FGFR3 IDH1 KMT2D
7 endocrine/exocrine gland MP:0005379 10.16 BRAF CCND1 CDK4 HRAS KRAS LIG4
8 neoplasm MP:0002006 10.1 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
9 integument MP:0010771 10.06 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
10 hearing/vestibular/ear MP:0005377 9.95 BRAF FGFR3 KMT2D KRAS PTPN11 TP53
11 limbs/digits/tail MP:0005371 9.91 BRAF FGFR3 IDH2 KRAS NRAS PTPN11
12 normal MP:0002873 9.91 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
13 pigmentation MP:0001186 9.63 BRAF CDK4 KRAS NRAS PTPN11 TP53
14 respiratory system MP:0005388 9.61 BRAF CCND1 FGFR3 HRAS IDH1 KMT2D
15 skeleton MP:0005390 9.4 BRAF CCND1 CDK4 FGFR3 HRAS IDH1
Sources

Drugs & Therapeutics for Myeloma, Multiple

About this section

Drugs for Myeloma, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 644)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apixaban Approved Phase 4 503612-47-3 10182969
2
Phentolamine Approved Phase 4 50-60-2 5775
3
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
4
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
5
Epirubicin Approved Phase 4 56420-45-2 41867
6
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
7
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
8
Ofloxacin Approved Phase 4 82419-36-1 4583
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
13
Pirarubicin Investigational Phase 4 72496-41-4
14 Anti-HIV Agents Phase 4
15 Anti-Retroviral Agents Phase 4
16 Plerixafor octahydrochloride Phase 4
17 Antithrombins Phase 4
18 Antithrombin III Phase 4
19 Serine Proteinase Inhibitors Phase 4
20 Factor Xa Inhibitors Phase 4
21 Penicillin G Benzathine Phase 4
22 Penicillin G Procaine Phase 4
23 penicillins Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Cyclooxygenase Inhibitors Phase 4
27 Antipyretics Phase 4
28 Platelet Aggregation Inhibitors Phase 4
29 Adjuvants, Immunologic Phase 4
30 Mitogens Phase 4
31 Hematinics Phase 4
32 Epoetin alfa Phase 4 113427-24-0
33
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
34
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
35
Pamidronate Approved Phase 3 40391-99-9 4674
36
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
37
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
38
Sulfamethoxazole Approved Phase 3 723-46-6 5329
39
Ethanol Approved Phase 3 64-17-5 702
40
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
41
Calcium carbonate Approved, Investigational Phase 3 471-34-1
42
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
44
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
45
Ifosfamide Approved Phase 3 3778-73-2 3690
46
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
47
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
48
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
50
deoxycholic acid Approved Phase 3 83-44-3 222528

Interventional clinical trials:

(show top 50) (show all 3001)
# Name Status NCT ID Phase Drugs
1 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Unknown status NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
2 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
3 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
4 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
5 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
6 Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma Completed NCT00622505 Phase 4 zoledronic acid
7 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
8 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
9 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
10 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
12 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
13 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Completed NCT01087008 Phase 4 zoledronic acid
14 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
15 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
16 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
17 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
18 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
19 REmoval of Free Light Chains in Hemodialysis Patients Without Multiple Myeloma. A Crossover COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
20 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
21 Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects Completed NCT02056210 Phase 4 Mozobil
22 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
23 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
24 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
25 Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Recruiting NCT04348006 Phase 4 Bortezomib 3.5 MG
26 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Recruiting NCT03768960 Phase 4 Daratumumab
27 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
28 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
29 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
30 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
31 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
32 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
33 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Active, not recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
34 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
35 A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy Not yet recruiting NCT03333551 Phase 4 F18 Florbetapir (amyvid) cardiac PET/CT imaging
36 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Not yet recruiting NCT04352439 Phase 4 Aspirin
37 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
38 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
39 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Terminated NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
40 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
41 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
42 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
43 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
44 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
45 A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma Unknown status NCT02916420 Phase 3 Pomalidomide;Dexamethasone
46 Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma Unknown status NCT00932217 Phase 3 filgrastim;lenograstim
47 A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
48 A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone
49 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
50 Hematopoietic Stem Cell Transplantation in Myeloma Unknown status NCT00415987 Phase 2, Phase 3

Search NIH Clinical Center for Myeloma, Multiple

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myeloma, Multiple cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myeloma, Multiple:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Peripheral blood stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Myeloma, Multiple:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: multiple myeloma

Sources

Genetic Tests for Myeloma, Multiple

About this section

Genetic tests related to Myeloma, Multiple:

# Genetic test Affiliating Genes
1 Multiple Myeloma 29 CCND1 LIG4
Sources

Anatomical Context for Myeloma, Multiple

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloma, Multiple:

19
Plasma Cells In Bone Marrow

MalaCards organs/tissues related to Myeloma, Multiple:

40
Bone, Bone Marrow, T Cells, B Cells, Kidney, Testes, Myeloid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myeloma, Multiple:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
Sources

Publications for Myeloma, Multiple

About this section

Articles related to Myeloma, Multiple:

(show top 50) (show all 30052)
# Title Authors PMID Year
1
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. 61 6 56
12471202 2002
2
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 61 56 6
9207791 1997
3
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. 56 61
28903037 2017
4
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. 56 61
27455953 2016
5
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. 61 56
23502783 2013
6
Initial genome sequencing and analysis of multiple myeloma. 56 61
21430775 2011
7
Multiple myeloma. 61 56
21410373 2011
8
Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. 56 61
19767238 2009
9
A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. 56 61
19405124 2009
10
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. 56 61
18594024 2008
11
IRF4 addiction in multiple myeloma. 56 61
18568025 2008
12
Familial myeloma. 56 61
18614782 2008
13
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. 61 56
17654686 2007
14
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). 61 6
11529856 2001
15
Familial multiple myeloma: report of fifteen families. 61 56
10354144 1999
16
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. 61 56
9326949 1997
17
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. 56 61
8943038 1996
18
Multiple myeloma in a pair of twins. 61 56
3814524 1987
19
Primary amyloidosis (AL) in families. 56 61
3706293 1986
20
Multiple myeloma in three siblings. 61 56
3927866 1985
21
Multiple myeloma in a pair of monozygotic twins: the first reported case. 61 56
3925983 1985
22
Familial immunopathies: report of nine families and survey of literature. 61 56
336182 1977
23
MULTIPLE MYELOMA IN SIBLINGS. 61 56
14180901 1964
24
KORNGOLD L: MULTIPLE MYELOMA IN 2 SISTERS. AN IMMUNOCHEMICAL STUDY. 56 61
14172080 1964
25
Multiple myeloma in sisters. 61 56
13766287 1961
26
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. 61 42
32359506 2020
27
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. 61 42
32470437 2020
28
The use of different dialysis membranes in therapy of patients with multiple myeloma. 61 42
32544311 2019
29
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. 61 46
19846888 2009
30
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 6
19855393 2009
31
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. 46 61
19401561 2009
32
An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. 6
18642369 2008
33
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. 46 61
18728182 2008
34
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. 61 46
18700954 2008
35
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 6
16841094 2006
36
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 6
16752380 2006
37
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
38
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. 56
14739213 2004
39
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. 6
12833394 2003
40
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 6
12624096 2003
41
Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. 56
11972529 2002
42
Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. 6
10073901 1999
43
Anticipation in familial plasma cell dyscrasias. 56
9858219 1998
44
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 6
9677066 1998
45
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 56
9482902 1998
46
The systemic amyloidoses. 56
9302305 1997
47
Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. 6
8858131 1996
48
Familial AL-amyloidosis in three Italian siblings. 56
8641636 1996
49
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. 6
7773297 1995
50
IgM monoclonal gammopathy and neuropathy in two siblings. 56
2852210 1988
Sources

Variations for Myeloma, Multiple

About this section

ClinVar genetic disease variations for Myeloma, Multiple:

6 (show top 50) (show all 197) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_001126112.2(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
4 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
5 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
6 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
7 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
8 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
9 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
10 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys)SNV Pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
11 PTPN11 NM_002834.5(PTPN11):c.227A>G (p.Glu76Gly)SNV Pathogenic 13338 rs121918465 12:112888211-112888211 12:112450407-112450407
12 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala)SNV Pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
13 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
14 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
15 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu)SNV Pathogenic,drug response 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
16 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
17 BRAF NM_001374258.1(BRAF):c.1526G>C (p.Gly509Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
18 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
19 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
20 FGFR3 NM_001163213.1(FGFR3):c.1954A>G (p.Lys652Glu)SNV Pathogenic 16331 rs78311289 4:1807889-1807889 4:1806162-1806162
21 FGFR3 NM_001163213.1(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
22 FGFR3 FGFR3, FGFR3/IGH FUSIONundetermined variant Pathogenic 16343
23 CDK4 NM_000075.4(CDK4):c.70C>T (p.Arg24Cys)SNV Pathogenic 16928 rs11547328 12:58145431-58145431 12:57751648-57751648
24 CDK4 NM_000075.4(CDK4):c.71G>A (p.Arg24His)SNV Pathogenic 16929 rs104894340 12:58145430-58145430 12:57751647-57751647
25 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 39648 rs121913237 1:115258747-115258747 1:114716126-114716126
26 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val)SNV Pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
27 NRAS NM_002524.5(NRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 40468 rs121913250 1:115258748-115258748 1:114716127-114716127
28 NRAS NM_002524.5(NRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 40469 rs121913250 1:115258748-115258748 1:114716127-114716127
29 NRAS NM_002524.5(NRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 40470 rs121913237 1:115258747-115258747 1:114716126-114716126
30 KRAS NM_033360.4(KRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic 45116 rs121913240 12:25380276-25380276 12:25227342-25227342
31 BRAF NM_001374258.1(BRAF):c.1526G>T (p.Gly509Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
32 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
33 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
34 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
35 NRAS NM_002524.5(NRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 177778 rs121913250 1:115258748-115258748 1:114716127-114716127
36 TP53 NM_001126112.2(TP53):c.216dup (p.Val73fs)duplication Pathogenic 182957 rs730882018 17:7579470-7579471 17:7676152-7676153
37 NRAS NM_002524.5(NRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 219097 rs121913237 1:115258747-115258747 1:114716126-114716126
38 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
39 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
40 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
41 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
42 KMT2D NM_003482.3(KMT2D):c.12844C>T (p.Arg4282Ter)SNV Pathogenic 372805 rs1057517992 12:49425644-49425644 12:49031861-49031861
43 TP53 NM_001126112.2(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
44 TP53 NM_001126112.2(TP53):c.713G>C (p.Cys238Ser)SNV Pathogenic 376575 rs730882005 17:7577568-7577568 17:7674250-7674250
45 TP53 NM_001126112.2(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
46 TP53 NM_001126112.2(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
47 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
48 TP53 NM_001126112.2(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
49 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
50 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val)SNV Pathogenic/Likely pathogenic 375876 rs121434596 1:115258744-115258744 1:114716123-114716123

Copy number variations for Myeloma, Multiple from CNVD:

7 (show top 50) (show all 303)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia
7 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
8 17467 1 142902432 245422432 Gain Multiple myeloma
9 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
10 20611 1 153300000 154800000 Gain EST1B Multiple myeloma
11 20700 1 1536308 6536308 Loss Multiple myeloma
12 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
13 20849 1 154800000 158800000 Gain CAPON Multiple myeloma
14 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
15 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
16 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
17 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
18 29497 1 23265113 23869113 Loss Multiple myeloma
19 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
20 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
21 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
22 31749 1 30500000 184000000 Gain Multiple myeloma
23 33943 1 50669458 53683458 Loss Multiple myeloma
24 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
25 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
26 36791 1 80821425 83677425 Loss Multiple myeloma
27 36969 1 84171854 96213854 Loss Multiple myeloma
28 37035 1 84700000 88100000 Gain Multiple myeloma
29 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
30 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
31 37525 10 30762871 30790767 Gain EST Multiple myeloma
32 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
33 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
34 41379 10 17300000 22600000 Gain and amplification Multiple myeloma
35 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
36 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
37 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
38 48574 11 100828925 102320925 Loss KIAA1377 Multiple myeloma
39 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
40 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
41 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
42 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
43 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
44 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
45 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
46 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
47 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
48 48584 11 100828925 102320925 Loss PORIMIN Multiple myeloma
49 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
50 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma
Sources

Expression for Myeloma, Multiple

About this section
Search GEO for disease gene expression data for Myeloma, Multiple.
Sources

Pathways for Myeloma, Multiple

About this section

Pathways related to Myeloma, Multiple according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myeloma, Multiple according to GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 65
Show member pathways
 13.58 PTPN11 NRAS KRAS KMT2D HRAS FGFR3
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.44 TP53 PTPN11 NRAS KRAS HRAS FGFR3
3
Phospholipase-C Pathway 63
Show member pathways
 13.14 TP53 NRAS KRAS HRAS FGFR3 BRAF
4
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.14 TP53 NRAS KRAS HRAS CDK4 CCND1
5
PI3K-Akt signaling pathway 36
Show member pathways
 13.06 TP53 NRAS KRAS HRAS FGFR3 CDK4
6
Human cytomegalovirus infection 36
Show member pathways
 13.02 TP53 NRAS KRAS HRAS CDK4 CCND1
7
Aldosterone synthesis and secretion 36
Show member pathways
 12.98 NRAS KRAS KMT2D HRAS CDK4 CCND1
8
Downstream signaling of activated FGFR2 65
Show member pathways
 12.93 PTPN11 NRAS KRAS HRAS FGFR3
9
Endometrial cancer 36
Show member pathways
 12.89 TP53 PTPN11 NRAS KRAS HRAS CDK4
10
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.85 PTPN11 KRAS HRAS CCND1 BRAF
11
MAPK signaling pathway 36 1
12.85 TP53 NRAS KRAS HRAS FGFR3 BRAF
12
Gastric cancer 36
Show member pathways
 12.83 TP53 NRAS KRAS HRAS CDK4 CCND1
13
Ras signaling pathway 36
Show member pathways
 12.82 PTPN11 NRAS KRAS HRAS FGFR3 BRAF
14
Pathways in cancer 36
12.82 TP53 NRAS KRAS HRAS FGFR3 CDK4
15
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.81 TP53 PTPN11 NRAS KRAS HRAS FGFR3
16
Development HGF signaling pathway 22
Show member pathways
 12.8 TP53 PTPN11 NRAS KRAS HRAS BRAF
17
nNOS Signaling in Skeletal Muscle 63
Show member pathways
 12.76 NRAS KRAS HRAS CDK4 CCND1
18
4-1BB Pathway 63
Show member pathways
 12.75 TP53 NRAS KRAS HRAS BRAF
19
Regulation of actin cytoskeleton 36 1
12.72 NRAS KRAS HRAS FGFR3 BRAF
20
Glioma 36
Show member pathways
 12.71 TP53 NRAS KRAS HRAS CDK4 CCND1
21
T cell receptor signaling pathway 36
Show member pathways
 12.69 PTPN11 NRAS KRAS HRAS CDK4
22
Immune response IL-23 signaling pathway 22
Show member pathways
 12.67 TP53 PTPN11 NRAS KRAS HRAS
23
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.64 PTPN11 NRAS KRAS HRAS FGFR3 BRAF
24
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.61 PTPN11 NRAS KRAS HRAS BRAF
25
VEGF Signaling 66
Show member pathways
 12.59 TP53 NRAS KRAS HRAS FGFR3
26
Oxytocin signaling pathway 36
Show member pathways
 12.59 NRAS KRAS HRAS CCND1 BRAF
27
Prolactin Signaling Pathway 36 1
Show member pathways
 12.58 PTPN11 NRAS KRAS HRAS CCND1
28
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.58 TP53 NRAS KRAS HRAS FGFR3 BRAF
29
ErbB signaling pathway 36 1
Show member pathways
 12.56 TP53 PTPN11 NRAS KRAS HRAS FGFR3
30
JAK-STAT signaling pathway 36
Show member pathways
 12.54 PTPN11 NRAS KRAS HRAS CCND1
31
Apoptosis Pathway 70
Show member pathways
 12.53 TP53 NRAS KRAS HRAS FGFR3
32
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.51 PTPN11 NRAS KRAS HRAS
33
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.5 PTPN11 NRAS KRAS HRAS BRAF
34
Development FGFR signaling pathway 22
Show member pathways
 12.49 PTPN11 NRAS KRAS HRAS FGFR3
35
Phospholipase D signaling pathway 36
Show member pathways
 12.47 PTPN11 NRAS KRAS HRAS
36
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.47 PTPN11 KRAS HRAS BRAF
37
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.47 NRAS KRAS HRAS FGFR3 BRAF
38
DNA Damage Response 1
Show member pathways
 12.47 TP53 MIR19A MIR106B CDK4 CCND1
39
Development IGF-1 receptor signaling 22
Show member pathways
 12.46 TP53 PTPN11 HRAS CCND1
40
CNTF Signaling 63
Show member pathways
 12.41 NRAS KRAS HRAS BRAF
41
Development EGFR signaling pathway 22
Show member pathways
 12.4 NRAS KRAS HRAS BRAF
42
Human T-cell leukemia virus 1 infection 36
12.39 TP53 NRAS KRAS